Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data

I. Faghmous, F. Nissen*, P. Kuebler, C. Flores, A.M. Patel, S.W. Pipe

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Aim: Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. Patients & methods: US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. Results: Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. Conclusion: This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.Tweetable abstract People with #hemophilia A are not protected against thrombotic events and should be monitored for thrombotic risk factors; the thrombotic risk of hemophilia A treatments should also be evaluated.
Original languageEnglish
Pages (from-to)1323-1336
Number of pages14
JournalJournal of Comparative Effectiveness Research
Issue number18
Early online date22 Oct 2021
Publication statusPublished - Oct 2021


  • hemophilia A
  • hemostasis
  • ischemic stroke
  • myocardial infarction
  • pulmonary embolism
  • therapeutics
  • thrombosis
  • vascular access devices
  • venous thrombosis


Dive into the research topics of 'Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data'. Together they form a unique fingerprint.

Cite this